Non-Interventional Study (NIS) Collecting Experiences For IPF in Taiwan
Latest Information Update: 09 Mar 2021
Price :
$35 *
At a glance
- Drugs Nintedanib (Primary) ; Pirfenidone
- Indications Idiopathic pulmonary fibrosis
- Focus Therapeutic Use
- Sponsors Boehringer Ingelheim
- 20 Apr 2020 Status changed from active, no longer recruiting to completed.
- 17 Jan 2019 Planned End Date changed from 31 Dec 2019 to 31 Mar 2020.
- 17 Jan 2019 Planned primary completion date changed from 31 Dec 2019 to 27 Feb 2020.